Once-daily dosing with budesonide/formoterol compared with twice-daily budesonide/formoterol and once-daily budesonide in adults with mild to moderate asthma

Respiratory Medicine

Volumn 100, Issue 12, 2006, Pages 2151-2159

  Kuna, P ^a   Creemers, J P H M ^b   Vondra, V ^c   Black, P N ^d   Lindqvist, A ^e   Nihlen, U ^f   Vogelmeier, C ^g  

^a N Barlicki University Hospital No 1 of Medical University of Lodz   (Poland)

^b CATHARINA HOSPITAL   (Netherlands)

^c Pulmonary and Allergology Clinic   (Czech Republic)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f LUND UNIVERSITY   (Sweden)

^g PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Asthma; Budesonide; Formoterol; Once daily; Symbicort

Indexed keywords

BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; SYMBICORT TURBUHALER;

ADULT; AGED; ARTICLE; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MILD PERSISTENT ASTHMA; MODERATE PERSISTENT ASTHMA; MORBIDITY; PATIENT COMPLIANCE; PEAK EXPIRATORY FLOW; PHARYNGITIS; PHARYNX DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RHINITIS; SYMPTOMATOLOGY; VIRUS INFECTION;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PEAK EXPIRATORY FLOW RATE; TREATMENT OUTCOME;

EID: 33750893156     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2006.03.016     Document Type: Article

References (33)

1. Pauwels R.A., Löfdahl C.-G., Postma D.S., Tattersfield A.E., O'Byrne P., Barnes P.J., et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 337 (1997) 1405-1411
2. O'Byrne P.M., Barnes P.J., Rodriguez-Roisin R., Runnerstrom E., Sandstrom T., Svensson K., et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 164 (2001) 1392-1397
3. Haughney J., Barnes G., Partridge M., and Cleland J. The Living & Breathing Study: a study of patients' views of asthma and its treatment. Primary Care Respir J 13 (2004) 28-35
4. Hyland M.E., and Ståhl E. Asthma treatment needs: a comparison of patients' and health professionals' perceptions. Clin Ther 26 (2004) 2141-2152
5. Zetterström O., Buhl R., Mellem H., Perpiñá M., Hedman J., and O'Neill S. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J 18 (2001) 262-268
6. Rosenhall L., Heinig J.H., Lindqvist A., Leegaard J., Ståhl E., and Bergqvist P.B. Budesonide/formoterol (Symbicort) is well tolerated and effective in patients with moderate persistent asthma. Int J Clin Pract 56 (2002) 427-433
7. Tal A., Simon G., Vermeulen J.H., Petru V., Cobos N., Everard M.L., et al. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatr Pulmonol 34 (2002) 342-350
8. Bateman E.D., Bantje T.A., Gomes M.J., Toumbis M.G., Huber R.M., Naya I., et al. Combination therapy with single inhaler budesonide/formoterol compared with high dose of fluticasone propionate alone in patients with moderate persistent asthma. Am J Respir Med 2 (2003) 275-281
9. Lalloo U.J., Malolepszy J., Kozma D., Krofta K., Ankerst J., Johansen B., et al. Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroids in adults with mild-to-moderate asthma. Chest 123 (2003) 1480-1487
10. O'Byrne P.M., Bisgaard H., Godard P.P., Pistolesi M., Palmqvist M., Zhu Y., et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 171 (2005) 129-136
11. Cochrane G.M. Compliance in asthma. Eur Respir Rev 8 (1998) 348-350
12. Buhl R., Creemers J.P.H.M., Vondra V., Martelli N.A., Naya I.P., and Ekstrom T. Once-daily budesonide/formoterol in a single inhaler in moderate persistent asthma. Respir Med 97 (2003) 323-330
13. Quanjer P.H., Tammeling G.J., Cotes J.E., Pedersen O.F., Peslin R., and Yernault J- C. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 16 (1993) 5-40
14. ® as maintenance therapy in asthmatic children. Eur Respir J 9 (1996) 1678-1683
15. Boulet L.P. Once-daily inhaled corticosteroids for the treatment of asthma. Curr Opin Pulm Med 10 (2004) 15-21
16. Radzik D., and Pavanello L. Inhaled steroids in the treatment of mild to moderate persistent asthma in children: once or twice daily administration?. Arch Dis Child 87 (2002) 415-416
17. Brusasco V., Crimi E., Gherson G., Nardelli R., Oldani V., Francucci B., et al. Actions other than smooth muscle relaxation may play a role in the protective effects of formoterol on the allergen-induced late asthmatic reaction. Pulm Pharmacol Ther 15 (2002) 399-406
18. Rabe K.F., Jörres R., Nowak D., Behr N., and Magnussen H. Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 h in bronchial asthma. Am Rev Respir Dis 147 (1993) 1436-1441
19. ®. Respir Med 92 (1998) 1017-1021
20. Palmqvist M., Persson G., Lazer L., Rosenborg J., Larson P., and Lotvall J. Inhaled dry-powder formoterol and salmeterol in asthmatic patients:onset of actions, duration of effect and potency. Eur Respir J 10 (1997) 2484-2489
21. Miller-Larsson A., Mattsson H., Hjertberg E., Dahlback M., Tunek A., and Brattsand R. Reversible fatty acid conjugation of budesonide. Novel mechanism for prolonged retention of topically applied steroid in airway tissue. Drug Metab Dispos 26 (1998) 623-630
22. Thorsson L., Thunnisen F.B.J.M., Korn S., Carlshaf S., Edsbäcker S., and Wouters E.F.M. Formation of fatty acid conjugates of budesonide in human lung tissue in vivo. Am J Respir Crit Care Med 157 (1998) A404
23. ® was as effective as twice-daily treatment in patients with mild to moderate persistent asthma. J Asthma 39 (2002) 203-210
24. ® to subjects with stable asthma. J Allergy Clin Immunol 104 (1999) 46-52
25. ® as initial therapy in patients with mild persistent asthma. Respir Med 93 (1999) 230-235
26. Campbell L.M., Gooding T.N., Aitchison W.R., Smith N., and Powell J.A. Initial loading (400 μg twice daily) versus static (400 μg nocte) dose budesonide for asthma management. PLAN Research Group. Int J Clin Pract 52 (1998) 361-370
27. Chisholm L., Dekker F.W., Knuistingh Neven A., and Petri H. Once-daily budesonide in mild asthma. Respir Med 92 (1998) 421-425
28. Venables T.L., Addlestone M.B., Smithers A.J., Blagden M.D., Weston D., Gooding T., et al. A comparison of the efficacy and patient acceptability of once daily budesonide via Turbuhaler and twice daily fluticasone propionate via disc-inhaler at an equal daily dose of 400 μg in adult asthmatics. Br J Clin Res 7 (1996) 15-32
29. ® once daily as initial prophylactic therapy for asthma. Respir Med 88 (1994) 293-299
30. Eisen S.A., Miller D.K., Woodward R.S., Spitznagel E., and Przybeck T.R. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 150 (1990) 1881-1884
31. Campbell L.M. Once-daily inhaled corticosteroids in mild to moderate asthma. Drugs 58 Suppl. 4 (1999) 25-33
32. Global Initiative for Asthma GINA. Global strategy for asthma management and prevention (NIH publication No. 02-3659) (2002), National Institutes of Health, National Heart, Lung, and Blood Institute, Washington, DC
33. Boulet L.-P. Perception of the role and potential side effects of inhaled corticosteroids among asthmatic patients. Chest 113 (1998) 587-592